RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
50 hedge funds and large institutions have $24.6M invested in RVL Pharmaceuticals plc Ordinary Shares in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
237% more capital invested
Capital invested by funds: $7.3M → $24.6M (+$17.3M)
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
25% more funds holding
Funds holding: 40 → 50 (+10)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.23M |
| 2 |
Renaissance Technologies
New York
|
+$2.02M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$809K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$616K |
| 5 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$512K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$864K |
| 2 |
Millennium Management
New York
|
-$269K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$179K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$168K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JAM
51
JW Asset Management
Miami Beach,
Florida
| – | -$864K | -225,000 | Closed |
|
|
52
Millennium Management
New York
| – | -$269K | -70,224 | Closed |
|
|
53
Citadel Advisors
Miami,
Florida
| – | -$179K | -46,594 | Closed |
|
54
Victory Capital Management
San Antonio,
Texas
| – | -$6K | -1,687 | Closed |
|
RVLP Hedge Fund Activity: Q4 2019 in Review
50 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2019, worth a combined $24.6M — up 237% from $7.3M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new RVLP positions and 4 closed out — a net gain of 10 holders — while 23 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $3.23M. The largest seller was JW Asset Management, exiting entirely with an estimated $864K sold.
- 50 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2019, up from 40 in Q3 2019.
- Funds reported $24.6M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2019, up 237% quarter-over-quarter.
- 14 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2019 and 4 closed out, a net change of +10 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2019 was BlackRock, an estimated $3.23M added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q4 2019 was JW Asset Management, an estimated $864K sold.
Based on aggregated 13F filings for Q4 2019.